Yu-Waye Chu - Apr 18, 2023 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Apr 18, 2023
Transactions value $
-$16,648
Form type
4
Date filed
4/19/2023, 04:07 PM
Previous filing
Feb 7, 2023
Next filing
Jul 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Sale -$1.4K -215 -0.15% $6.52 143K Apr 18, 2023 Direct F1, F2
transaction FATE Common Stock Sale -$15.2K -2.32K -1.62% $6.58 141K Apr 18, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 7,500 shares of Common Stock underlying RSUs granted to the Reporting Person on April 15, 2019. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.
F2 Represents the weighted average sale price of the shares sold from $6.46 to $6.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 2-3.
F3 Represents the weighted average sale price of the shares sold from $6.56 to $6.60 per share.